Valuation is the primary point of negotiation in any private equity (PE) transaction. It determines how value and potential returns are distributed between the seller, management, and the fund’s limited partners. In public markets, a company’s value is set in real time by trading prices. In contrast, value is determined using three core valuation frameworks in private markets. These key approaches include comparable companies, precedent transactions, and discounted cash flows, applied to the specific business and market conditions. However, there is no single answer to determine a business's value, as it depends on its capital structure, return targets, and today’s market backdrop. Therefore, understanding how these methods work and why they can yield very different answers is crucial for investors determining whether a sponsor is paying a reasonable price.
Before going into the various methods, it is important to clarify what exactly is being valued. Private equity buyers tend to focus on enterprise value (EV), and not just equity value. Enterprise value refers to the value of the entire business, regardless of how it is financed. It is usually calculated as the equity value, including debt and other debt-like items, excluding excess cash. In comparison, equity value refers to what shareholders actually acquire when the deal closes, after adjusting for those balance sheet items.
This distinction matters because most PE deals are negotiated on a “cash-free, debt-free” basis. In practice, the buyer and seller first agree on an enterprise value, usually based on a multiple of earnings. Then, at closing, the price is adjusted for cash, debt, and working capital to determine the final equity value paid to shareholders.
The earnings metric at the center of this negotiation is typically always EBITDA, earnings before interest, taxes, depreciation, and amortization. EBITDA estimates operating cash flow before the impact of capital structure, tax planning, and non-cash charges. Thus, making it a useful, though imperfect, way to gauge a company’s ability to generate cash. Further, EV/EBITDA multiples allow PE investors to compare businesses with different capital structures on a more level playing field.
EBITDA multiples vary widely by industry and business quality. Healthcare companies often trade at around 10-14x because demand is consistent and revenue is predictable. High-growth tech companies, particularly those with subscription models, can even reach 12-18x or higher. However, more cyclical industries, such as industrial companies, tend to have lower multiples, usually around 6-9x. Factors such as growth, stable revenue, reliance on a few customers, and the strength of the management team all influence where a company falls within these ranges.
Comparable company analysis, or “trading comps,” begins with the consideration of how similar public companies are valued in today’s market, and what that means for private businesses. Analysts begin by focusing on building a peer group of publicly traded businesses with similar models, end markets, growth profiles, and margin structures. They then calculate valuation ratios, such as EV/EBITDA and EV/revenue when relevant, using market prices and reported financials. These estimates then show the range of values companies are receiving in the market. After adjusting for differences in size, growth, and profitability, investors apply a fitting EBITDA multiple to estimate the company’s enterprise value.
Trading comps help anchor these valuations to current market conditions. Notably, when public company valuations rise due to low interest rates, strong earnings, or sector excitement, private company valuations tend to follow suit. For example, when public software companies trade at very high valuations, private SaaS companies are usually priced more aggressively as investors compete for limited opportunities. However, when market sentiment weakens, the same company can appear 20-30 percent less valuable even if the business itself has had no dramatic changes.
Precedent transaction analysis, or “deal comps,” refers to what multiples buyers have recently paid to acquire similar businesses. This method evaluates completed mergers and acquisitions that involve similar companies in the same industry. Analysts compare factors such as size, location, and business model to then calculate valuation multiples by dividing the company’s value by its EBITDA or revenue. Since these deals involve full acquisitions, the multiples tend to be higher than public-market valuations, as buyers are paying for control of the company.
Precedent transactions entail two factors that trading comparables might miss. First, they show what buyers have actually been willing to pay to obtain control of a company. Second, they reflect potential advantages from the combined companies, such as cost savings or new revenue opportunities. For example, a strategic buyer may expect cost savings, access to new customers, or opportunities to sell additional products through the acquisition, which can help justify paying a higher price than a financial buyer would.
Thus, this element helps explain how the same company can receive different valuations from different buyers. A corporate buyer with intersecting operations may be willing to pay a higher EBITDA multiple because joining the businesses could lead to cost savings or additional revenue opportunities. Those benefits effectively lessened the real cost of the deal over time. Furthermore, a financial sponsor without those advantages may offer less, as it must rely more on returns generated by the company itself and on the limitations of available debt financing.
The third major valuation method is discounted cash flow (DCF) analysis, which determines a company’s value based on the cash it is predicted to generate in the future rather than market multiples. In private equity, these future cash flows are often modeled using a leveraged buyout (LBO) framework to evaluate the investment from the buyer’s perspective.
Sponsors project the company’s revenue, expenses, investment needs, and working capital over the next five to seven years in line with their plan to improve the business. They then consider how the deal will be financed, including the amount of debt to be used, its cost, and the repayment schedule. After that, they estimate how much cash the investment could potentially generate over time. Finally, they determine a future sale price by applying an EBITDA multiple to the company’s projected earnings and use that to calculate the expected return on the investment at various purchase prices.
In practice, DCF analysis helps sponsors determine whether a deal price can realistically produce their target returns. Bain & Company’s 2026 Global Private Equity Report found that deals today often require 10-12 percent annual EBITDA growth to achieve strong returns, compared with about 5 percent a decade ago. If the purchase price is deemed too high, even a strong operational plan may not yield sufficient returns. However, at a lower price, the same business plan can become increasingly attractive to investors.
When these valuation methods are combined, it becomes clear how the same company can receive very different valuations. One major factor is the type of buyer involved. Strategic buyers or experienced platform investors may be inclined to pay more because they expect cost savings, growth opportunities, or operational advantages after the acquisition. A buyer’s financing strategy and return expectations also influence valuation. Buyers who use more leverage or are more willing to accept lower return targets can often justify higher purchase prices. In addition, the deal structure plays an important role. Earnouts, seller financing, and rollover equity can help bridge valuation gaps by allocating part of the payment to future performance rather than increasing the upfront price. Another key influence on valuations is market conditions. For example, strong competition, ample capital, and rising deal activity can all push prices higher, while high interest rates or weaker financing markets can reduce buyer demand and lower valuations. Therefore, it is highly recommended that investors understand how these different factors affect the sponsor’s valuation and whether the deal still offers an appealing balance of risk and return.
Finally, it is crucial to understand that a “12x EBITDA” valuation is only the starting point and doesn’t reflect the exact amount the seller ultimately receives in the deal. Most transactions start with an agreed enterprise value, generally expressed as a multiple of trailing or projected EBITDA on a cash-free, debt-free basis. Then, the price is altered in accordance with the company’s financial position at closing. Cash on the balance sheet is then added, while debt and debt-like obligations are subtracted to estimate the final equity value.
The buyer and seller also agree on a target level of working capital, usually based on historical averages. If the company’s actual working capital at closing falls short of that target, the purchase price is reduced. In contrast, if the company exceeds the given target, the price will increase. In some cases, earnouts or other contingent payments are included, which means that part of the seller’s payout depends on the company’s performance after the transaction is completed.
For investors evaluating private equity opportunities, the primary focus should not be centered on whether a deal appears cheap or expensive based on a single multiple. Rather, investors must assess factors such as whether the sponsor’s valuation, deal structure, and operational plan reflect a disciplined approach capable of generating strong returns over time.